Genetic polymorphisms in glutathione S-transferase μ and θ, N- acetyltransferase, and CYP1A1 and risk of gliomas

Zoltan Trizna, Mariza De Andrade, Athanassios P. Kyritsis, Katrina Briggs, Victor A. Levin, Janet M. Bruner, Qingyi Wei, Melissa L. Bondy

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The role of genetic polymorphisms in modulating susceptibility to carcinogenic exposures has been well explored for tobacco-related neoplasms but not for other neoplasms including gliomas. It is relevant to explore these polymorphisms because certain carcinogenic exposures such as nitrosamines are implicated in the risk of gliomas. We therefore conducted a pilot case-control study to examine the role of polymorphisms in GSTM1, GSTT1, NAT2 (rapid, intermediate, and slow acetylation), and CYP1A1 and risk of glioma. Ninety patients diagnosed with glioma were ascertained as part of an ongoing genetic epidemiological study and were age, gender, and race matched with 90 healthy controls. We used PCR based methodology to determine the prevalence of the above genetic polymorphisms using sequences and PCR conditions directly adapted from studies reported previously. We calculated univariate odds ratios and performed multiple logistic regression to assess interactions between polymorphisms. We found no statistically significant associations between the null genotypes of GSTM1 and GSTT1, and CYP1A1 and risk of gliomas. However, there was an intriguing pattern with NAT2 acetylation status (odds ratios, 1.81, 1.34, and 0.61 for rapid, intermediate, and slow acetylation, respectively; P = 0.10 for trend). It is unlikely that any single polymorphism is sufficiently predictive of risk, and a panel of markers integrated with epidemiological data should be conducted on a large number of study subjects to fully understand the role of genetic polymorphisms and brain tumor risk.

Original languageEnglish (US)
Pages (from-to)553-555
Number of pages3
JournalCancer Epidemiology Biomarkers and Prevention
Volume7
Issue number6
StatePublished - Jun 1998
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP1A1
Acetyltransferases
Genetic Polymorphisms
Glutathione Transferase
Glioma
Acetylation
Odds Ratio
Nitrosamines
Polymerase Chain Reaction
Brain Neoplasms
Tobacco
Case-Control Studies
Epidemiologic Studies
Neoplasms
Logistic Models
Genotype

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Genetic polymorphisms in glutathione S-transferase μ and θ, N- acetyltransferase, and CYP1A1 and risk of gliomas. / Trizna, Zoltan; De Andrade, Mariza; Kyritsis, Athanassios P.; Briggs, Katrina; Levin, Victor A.; Bruner, Janet M.; Wei, Qingyi; Bondy, Melissa L.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 7, No. 6, 06.1998, p. 553-555.

Research output: Contribution to journalArticle

Trizna, Z, De Andrade, M, Kyritsis, AP, Briggs, K, Levin, VA, Bruner, JM, Wei, Q & Bondy, ML 1998, 'Genetic polymorphisms in glutathione S-transferase μ and θ, N- acetyltransferase, and CYP1A1 and risk of gliomas', Cancer Epidemiology Biomarkers and Prevention, vol. 7, no. 6, pp. 553-555.
Trizna, Zoltan ; De Andrade, Mariza ; Kyritsis, Athanassios P. ; Briggs, Katrina ; Levin, Victor A. ; Bruner, Janet M. ; Wei, Qingyi ; Bondy, Melissa L. / Genetic polymorphisms in glutathione S-transferase μ and θ, N- acetyltransferase, and CYP1A1 and risk of gliomas. In: Cancer Epidemiology Biomarkers and Prevention. 1998 ; Vol. 7, No. 6. pp. 553-555.
@article{2a47790a3cfe49ba8540e6aea7251404,
title = "Genetic polymorphisms in glutathione S-transferase μ and θ, N- acetyltransferase, and CYP1A1 and risk of gliomas",
abstract = "The role of genetic polymorphisms in modulating susceptibility to carcinogenic exposures has been well explored for tobacco-related neoplasms but not for other neoplasms including gliomas. It is relevant to explore these polymorphisms because certain carcinogenic exposures such as nitrosamines are implicated in the risk of gliomas. We therefore conducted a pilot case-control study to examine the role of polymorphisms in GSTM1, GSTT1, NAT2 (rapid, intermediate, and slow acetylation), and CYP1A1 and risk of glioma. Ninety patients diagnosed with glioma were ascertained as part of an ongoing genetic epidemiological study and were age, gender, and race matched with 90 healthy controls. We used PCR based methodology to determine the prevalence of the above genetic polymorphisms using sequences and PCR conditions directly adapted from studies reported previously. We calculated univariate odds ratios and performed multiple logistic regression to assess interactions between polymorphisms. We found no statistically significant associations between the null genotypes of GSTM1 and GSTT1, and CYP1A1 and risk of gliomas. However, there was an intriguing pattern with NAT2 acetylation status (odds ratios, 1.81, 1.34, and 0.61 for rapid, intermediate, and slow acetylation, respectively; P = 0.10 for trend). It is unlikely that any single polymorphism is sufficiently predictive of risk, and a panel of markers integrated with epidemiological data should be conducted on a large number of study subjects to fully understand the role of genetic polymorphisms and brain tumor risk.",
author = "Zoltan Trizna and {De Andrade}, Mariza and Kyritsis, {Athanassios P.} and Katrina Briggs and Levin, {Victor A.} and Bruner, {Janet M.} and Qingyi Wei and Bondy, {Melissa L.}",
year = "1998",
month = "6",
language = "English (US)",
volume = "7",
pages = "553--555",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Genetic polymorphisms in glutathione S-transferase μ and θ, N- acetyltransferase, and CYP1A1 and risk of gliomas

AU - Trizna, Zoltan

AU - De Andrade, Mariza

AU - Kyritsis, Athanassios P.

AU - Briggs, Katrina

AU - Levin, Victor A.

AU - Bruner, Janet M.

AU - Wei, Qingyi

AU - Bondy, Melissa L.

PY - 1998/6

Y1 - 1998/6

N2 - The role of genetic polymorphisms in modulating susceptibility to carcinogenic exposures has been well explored for tobacco-related neoplasms but not for other neoplasms including gliomas. It is relevant to explore these polymorphisms because certain carcinogenic exposures such as nitrosamines are implicated in the risk of gliomas. We therefore conducted a pilot case-control study to examine the role of polymorphisms in GSTM1, GSTT1, NAT2 (rapid, intermediate, and slow acetylation), and CYP1A1 and risk of glioma. Ninety patients diagnosed with glioma were ascertained as part of an ongoing genetic epidemiological study and were age, gender, and race matched with 90 healthy controls. We used PCR based methodology to determine the prevalence of the above genetic polymorphisms using sequences and PCR conditions directly adapted from studies reported previously. We calculated univariate odds ratios and performed multiple logistic regression to assess interactions between polymorphisms. We found no statistically significant associations between the null genotypes of GSTM1 and GSTT1, and CYP1A1 and risk of gliomas. However, there was an intriguing pattern with NAT2 acetylation status (odds ratios, 1.81, 1.34, and 0.61 for rapid, intermediate, and slow acetylation, respectively; P = 0.10 for trend). It is unlikely that any single polymorphism is sufficiently predictive of risk, and a panel of markers integrated with epidemiological data should be conducted on a large number of study subjects to fully understand the role of genetic polymorphisms and brain tumor risk.

AB - The role of genetic polymorphisms in modulating susceptibility to carcinogenic exposures has been well explored for tobacco-related neoplasms but not for other neoplasms including gliomas. It is relevant to explore these polymorphisms because certain carcinogenic exposures such as nitrosamines are implicated in the risk of gliomas. We therefore conducted a pilot case-control study to examine the role of polymorphisms in GSTM1, GSTT1, NAT2 (rapid, intermediate, and slow acetylation), and CYP1A1 and risk of glioma. Ninety patients diagnosed with glioma were ascertained as part of an ongoing genetic epidemiological study and were age, gender, and race matched with 90 healthy controls. We used PCR based methodology to determine the prevalence of the above genetic polymorphisms using sequences and PCR conditions directly adapted from studies reported previously. We calculated univariate odds ratios and performed multiple logistic regression to assess interactions between polymorphisms. We found no statistically significant associations between the null genotypes of GSTM1 and GSTT1, and CYP1A1 and risk of gliomas. However, there was an intriguing pattern with NAT2 acetylation status (odds ratios, 1.81, 1.34, and 0.61 for rapid, intermediate, and slow acetylation, respectively; P = 0.10 for trend). It is unlikely that any single polymorphism is sufficiently predictive of risk, and a panel of markers integrated with epidemiological data should be conducted on a large number of study subjects to fully understand the role of genetic polymorphisms and brain tumor risk.

UR - http://www.scopus.com/inward/record.url?scp=0031928096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031928096&partnerID=8YFLogxK

M3 - Article

C2 - 9641501

AN - SCOPUS:0031928096

VL - 7

SP - 553

EP - 555

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -